Dr. Herman Weiss
Sep 25, 2026
Three papers this cycle, each with a practical edge: a huge Danish study that finally puts clean numbers on the pill-versus-patch question, the most complete analysis yet of what diet and exercise actually accomplish in PMOS, and a Nature Medicine paper that found the molecular fingerprint menopause leaves in blood - and tied it to brain aging. Then your feeds: women are buying gray-market peptides with code names, and PMOS just had its biggest mainstream media week since the renaming. I read the science so you don't have to.
Oral vs transdermal hormone therapy: the cleanest clot numbers yet. Researchers mined Denmark's national health registries for every woman aged 50 to 69 between 2003 and 2021 with a first blood clot, stroke, or heart attack - nearly 10,000 clot cases, over 18,000 strokes, almost 12,000 heart attacks - and matched each against women without those events, then compared their prescriptions. Published September 23 in The BMJ. The headline: oral hormone therapy was linked to higher clot risk regardless of dose or how long it was used, while patches, gels, and sprays showed no general increase in clot risk at any dose or duration. The absolute numbers keep it honest: one extra clot per year for every 1,055 women on oral therapy, one extra stroke per 1,642, one extra heart attack per 3,846 - and the stroke and heart attack risk lived almost entirely in high-dose pills (above 1 mg estradiol a day) taken for more than a year. What this means: small risks, real differences by route. If you're on oral therapy and have any clot risk factors, this study is a good reason to ask your doctor whether a patch would do the same job with less baggage. The limits: registries can't capture every confounder, the transdermal group was smaller, and one subgroup (combined cyclic therapy through the skin) showed a heart-attack signal on sparse data - worth watching, not worth panicking over. For my PMOS readers, a detail worth knowing: this study deliberately excluded women with a PCOS diagnosis. The biggest safety dataset we have doesn't directly include you, and your baseline clot risk already runs higher than average - so the route question deserves an explicit conversation, not an assumption. (Contemporary menopausal hormone therapy and thrombotic disease: nationwide nested case-control study. BMJ. 2026. doi:10.1136/bmj-2026-100688)
Lifestyle treatment in PMOS: what the trials actually add up to. Olalere and colleagues updated the evidence base behind the international PMOS guideline with every randomized trial of diet, exercise, or behavioral programs - 34 trials, 1,871 women, published September 23 in PLOS Medicine. Women in lifestyle programs were four times as likely to regain regular cycles (odds ratio 4.03), and lost on average 2.4 cm off waist circumference, with small but real improvements in fasting glucose and fasting insulin. The useful detail: different tools did different jobs - exercise was best for waist size and insulin, diet was best for glucose, and women with overweight saw the widest benefits, including lower testosterone and better cholesterol. What this means: lifestyle treatment in PMOS is not a lecture, it's a therapy with measurable effects - but the honest caveats travel with it. That fourfold increase in regular cycles comes from just 5 small trials with a wide confidence range, a third of the studies had a high risk of bias, and the trials disagreed with each other a lot. And reproductive outcomes beyond cycle regularity - pregnancy, live birth - were barely reported at all. For my menopause readers: notice what's happening here. The first-line therapy for the most common hormone condition of young women is the same one your doctor gives you at fifty - food, movement, behavior - and the evidence says it works modestly in both decades, which is why how it's prescribed matters as much as what. (Olalere O, et al. PLOS Med. 2026. doi:10.1371/journal.pmed.1004887)
The blood signature of menopause, mapped to the aging brain. Wood Alexander, Rabin, and colleagues asked a deceptively simple question in Nature Medicine (September 22): does menopause leave a readable fingerprint in blood proteins, and does it connect to brain aging? In 80 carefully staged women aged 43 to 58, they found menopause-linked disruption in inflammatory, synaptic, metabolic, and Alzheimer-related protein pathways - and these shifts tracked with hormone levels more strongly than with age itself. Women with hot flashes showed especially strong pro-inflammatory signals. The finding held up in a 2,814-woman validation sample, and across four cohorts totaling nearly 12,000 older women, a higher "menopause proteomic score" predicted worse cognitive aging and higher dementia risk. What this means: menopause is not just a reproductive event - it's a whole-body molecular event that shows up in the blood and lines up with the biology of the aging brain. Down the road, this is how a midlife blood test for brain-risk could actually get built. The limits: associations, not causes - nobody knows yet whether calming the protein shifts (with hormones, exercise, or anything else) changes the dementia outcome, and the discovery group was small. For my PMOS readers: chronic low-grade inflammation is already a feature of PMOS in your twenties and thirties. Menopause appears to stack a second inflammatory shift on top. Managing inflammation and metabolism early isn't vanity - it's brain insurance. (Wood Alexander M, Rabin JS, et al. Nat Med. 2026. doi:10.1038/s41591-026-04648-4)
What's trending this week - and how it holds up. Two things are moving. First, grounded: the New York Post published an investigation into women treating menopause symptoms with gray-market peptides bought online - "research use only" vials, self-designed protocols, and a whole coded vocabulary ("peppers" for peptides, "ratatouille" for retatrutide) built to dodge TikTok and Instagram moderation. A Nautilus piece the same week maps how fast peptide content is spreading on social platforms. The honest read: none of these products has a menopause trial behind it, dosing is guesswork, and quality control is nil. But I'd rather be honest about why it's happening - the same care gap the Senate heard about two weeks ago. When the system leaves women symptomatic and unheard, the gray market writes its own protocols. Bring me the vial before you inject it; I'd rather know than have you hide it. Second, grounded: PMOS had its biggest mainstream week since the renaming - National Geographic asked "Are We Treating PMOS All Wrong?" and Women's Health ran new survey research on diagnostic delays, weight bias, and eating-disorder risk in PMOS care, finding years-long delays and advice that often amounts to "lose weight" delivered as blame. Where the chatter matches the evidence: the lifestyle meta-analysis above says diet and exercise genuinely help - and the survey data says how that advice is delivered is breaking patients. Both are true at once. That's the whole argument for treating these two audiences - and their doctors - as one community.
That's the cycle. Bring your doctor the papers, not just the headlines - and if the headlines come in code words, bring those too.
Dr. Herman Weiss
Medical Disclaimer
The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health-care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here. Use of this content does not create a doctor-patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.